Xi’an Alena Biotechnology Co., Ltd entered into a share transfer agreement to acquire 80% stake in Shaanxi Chaoying Bio-Technology Co., Ltd. from Cybrdi, Inc. (OTCPK:CYDI) for CNY 25.6 million on July 19, 2017. The other shareholders of Shaanxi Chaoying Bio-Technology, Shannxi Yanfeng Real Estate Development Co., Ltd, Shannxi Chaoying Cosmetics Co., Ltd, and Immuno-Oncocemomics Inc. had given up their respective rights of first refusal to purchase the equity interest held by Cybrdi in Shaanxi Chaoying Bio-Technology. The penalty for breach of the agreement is 5% of the consideration of the transaction. Transaction is subject to parties complete all procedures as set out in the agreement, and 80% of the equity interest of Shaanxi Chaoying Bio-Technology is transferred to Xi’an Alena Biotechnology and Register of Shareholders, Articles of Association, and company registration files of Shaanxi Chaoying Bio-Technology have been clearly updated to reflect that Cybrdi owns that amount of equity interest. Xi’an Alena Biotechnology Co., Ltd completed the acquisition of 80% stake in Shaanxi Chaoying Bio-Technology Co., Ltd. from Cybrdi, Inc. (OTCPK:CYDI) in October 2017. Xi’an Alena Biotechnology paid Cybrdi 47% of the consideration under the agreement by December, 2017, after Shaanxi Chaoying Bio-Technology and Cybrdi had completed the necessary regulatory registration procedures, and is expected to pay the balance of the consideration.